Арилжаа Aligos Therapeutics, Inc. - ALGS CFD

Арилжааны нөхцөл

• Төрөл: CFD
• Спред: 0.1784
• Лонг позицын шөнийн санхүүжилтийн тохируулга: -0.02157%
• Шорт позицын нэг шөнийн санхүүжилтийн тохируулга: -0.00065%
• Шөнийн санхүүжилтийг тохируулах хугацаа: 22:00 (UTC)
• Валют: USD
• Арилжаалсан доод хэмжээ: 1
• Маржин: 5.00%
• Хөрөнгийн бирж: United States of America
• Арилжааны шимтгэл: 0%
• Баталгаат стопын шимтгэл: 1%

Гол үзүүлэлтүүд

• Өмнөх Хаах: 7.9958
• Нээх: 7.8658
• 1 жилийн өөрчлөлт: -74.01%
• Өдрийн диапазон: 7.8458 - 8.3058

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a synthetic oligonucleotide that is in Phase I clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company is also developing ALG-020572, an antisense oligonucleotide to decrease HBsAg levels; and ALG-055009, a small molecule THR-ß agonist for the treatment of non-alcoholic steatohepatitis. In addition, it is developing siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. The company has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting SARS-CoV-2; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It has research partnership with Vipergen ApS to develop DNA Encoded Library (DEL)-based drug discovery for viral infections and liver diseases. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.